Skip to main content
. 2020 Sep 11;13(9):242. doi: 10.3390/ph13090242

Figure 4.

Figure 4

Compounds in phase III clinical trials in 2019, classified by mechanism of action. The agents in green are biologic, in blue are small molecules, and in orange are symptomatic agents designed to treat AD associated symptoms or cognitive enhancement. Adapted from [23].